Your browser doesn't support javascript.
loading
Challenges in IBD Research 2024: Novel Technologies.
Prasad, Shalini; Cross, Raymond K; Monroe, Mary Beth; Dolinger, Michael T; Motte, Rachel; Hong, Sungmo; Stidham, Ryan W; Kumar, Narendra; Levine, Deborah; Larijani, Anthony; Simone, Ashley; Chachu, Karen A; Wyborski, Russell; Heller, Caren A; Moss, Alan C; Schwerbrock, Nicole M J; Selaru, Florin M.
Afiliação
  • Prasad S; Department of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
  • Cross RK; Director of the Inflammatory Bowel Disease Program, University of Maryland School of Medicine, Maryland, MD, USA.
  • Monroe MB; Department of Biomedical and Chemical Engineering BioInspired Syracuse: Institute for Material and Living Systems, Syracuse University, Syracuse, NY, USA.
  • Dolinger MT; Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology, New York, NY, USA.
  • Motte R; TISSIUM, 74 Rue du Faubourg Saint-Antoine, Paris, France.
  • Hong S; Department of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
  • Stidham RW; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
  • Kumar N; Department of Pharmaceutical Science, ILR-College of Pharmacy, Texas A&M University, TX, USA.
  • Levine D; Department of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
  • Larijani A; Department of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
  • Simone A; Department of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
  • Chachu KA; Department of Medicine, Division of Gastroenterology, Duke University School of Medicine, Durham, NC, USA.
  • Wyborski R; Members of the Crohn's & Colitis Foundation, New York, NY, USA.
  • Heller CA; Members of the Crohn's & Colitis Foundation, New York, NY, USA.
  • Moss AC; Members of the Crohn's & Colitis Foundation, New York, NY, USA.
  • Schwerbrock NMJ; Members of the Crohn's & Colitis Foundation, New York, NY, USA.
  • Selaru FM; Division of Gastroenterology, Oncology and Biomedical Engineering, Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD, USA.
Inflamm Bowel Dis ; 30(Supplement_2): S30-S38, 2024 May 23.
Article em En | MEDLINE | ID: mdl-38778625
ABSTRACT
Novel technology is one of the five focus areas of the Challenges in Inflammatory Bowel Disease (IBD) Research 2024 document. Building off the Challenges in IBD Research 2019 document, the Foundation aims to provide a comprehensive overview of current gaps in IBD research and deliver actionable approaches to address them with a focus on how these gaps can lead to advancements in interception, remission, and restoration for these diseases. The document is the result of a multidisciplinary collaboration from scientists, clinicians, patients, and funders and represents a valuable resource for patient-centric research prioritization. Specifically, the Novel Technologies section focuses on addressing key research gaps to enable interception and improve remission rates in IBD. This includes testing predictions of disease onset and progression, developing novel technologies tailored to specific phenotypes, and facilitating collaborative translation of science into diagnostics, devices, and therapeutics. Proposed priority actions outlined in the document include real-time measurement of biological changes preceding disease onset, more effective quantification of fibrosis, exploration of technologies for local treatment of fistulas, and the development of drug delivery platforms for precise, location-restricted therapies. Additionally, there is a strong emphasis on fostering collaboration between various stakeholders to accelerate progress in IBD research and treatment. Addressing these research gaps necessitates the exploration and implementation of bio-engineered novel technologies spanning a spectrum from materials to systems. By harnessing innovative ideas and technologies, there's a collective effort to enhance patient care and outcomes for individuals affected by IBD.
Technology drives medical progress, solving clinical challenges and enhancing patient care in inflammatory bowel disease (IBD). Collaborative efforts focus on addressing research gaps to improve interception, restoration, and remission rates, utilizing innovative technologies for better patient outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article